5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer

5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer

EMJ

3 years
540 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the 5-year disease-free survival, defined as relapse, secondary malignancy or death, of patients with node-positive and high-risk node-negative early breast cancer who omitted adjuvant chemotherapy based on an Oncotype DX® 21-gene Recurrence Score® result of 11 or less in PlanB, a prospective phase 3 trial evaluating the Recurrence Score® result.

This content is supported by Genomic Health, Inc.



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay